Dr Reddys launches generic Librax in US

Written by Ruchika Sharma Published On 2021-08-31T14:55:42+05:30 | Updated On 31 Aug 2021 2:55 PM IST

Hyderabad: Drugmaker, Dr Reddy's Laboratories Ltd., today announced the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg in US.

The product is a therapeutic equivalent generic version of Librax (chlordiazepoxide hydrochloride and clidinium bromide) approved by the U.S. Food and Drug Administration (USFDA).

Dr Reddy's Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100.

The Librax brand and generic market had U.S. sales of approximately $105.9 million MAT for the most recent twelve months ending in July 2021 according to IQVIA Health.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.

Read also: Dr Reddys to sell migraine drug Elyxyb rights in US, Canada to BioDelivery Sciences International

chlordiazepoxide hydrochloride and clidinium bromide capsuleslibraxusfdadr reddy's labsdr reddy's labs news

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751